Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors

The Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic parameters, and a favorable safety profile in Indian patients with Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Risk Factors, according to a recent study published in the November 2025 issue of Cureus.This retrospective, single-center study evaluated 101 T2DM patients prescribed the Dapagliflozin –Vildagliptin FDC over a three-month period. Of these, 49 patients completed the follow-up and were included in the final analysis. Patients were on existing antidiabetic therapy, with the FDC added as an add-on treatment.Key findings of the study are:1.Glycemic Control: Mean HbA1c decreased from 8.87% at baseline to 7.22%, a reduction of 1.65%. Fasting plasma glucose decreased by 68.14 mg/dL, and postprandial glucose dropped by 122.45 mg/dL, showing a pronounced post-meal glucose-lowering effect. The benefits were consistent across age groups, obesity status, disease duration, and comorbidities.2.Metabolic Parameters: Total cholesterol, LDL-C, triglycerides, and HDL-C improved significantly. Liver enzymes ALT and AST also showed marked reductions, reflecting favorable hepatic outcomes.3.Safety Profile: The FDC was well tolerated, with mild adverse events reported in a few patients, including gastrointestinal discomfort (2%), genitourinary infection (1.5%), and mild hypoglycemia (1.5%). No severe events, liver, or renal complications were observed.Dapagliflozin 5 mg + Vildagliptin 50 mg FDC offers a safe and effective option for improving glycemic and metabolic outcomes in T2DM Patients with CV Risk Factors.Adapted from:Sanghvi A, Warrier S (November 18,
2025) Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and
Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective
Study. Cureus 17(11): e97192. DOI 10.7759/cureus.97192